Optimizing patient expectancy in the pharmacologic treatment of major depressive disorder

被引:0
|
作者
Zilcha-Mano, Sigal [1 ]
Brown, Patrick J. [2 ]
Roose, Steven P. [2 ]
Cappetta, Kiley [2 ]
Rutherford, Bret R. [2 ]
机构
[1] Univ Haifa, Dept Psychol, IL-31905 Haifa, Israel
[2] Columbia Univ Coll Phys & Surg, New York State Psychiat Inst, New York, NY 10032 USA
关键词
expectancy; major depressive disorder; placebo effects; PLACEBO-RESPONSE; BETWEEN-PERSON; WITHIN-PERSON; METAANALYSIS; DESIGN; ALLIANCE; QUESTION; MODELS;
D O I
10.1017/S0033291718003343
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Background Patient expectancy is an important source of placebo effects in antidepressant clinical trials, but all prior studies measured expectancy prior to the initiation of medication treatment. Little is known about how expectancy changes during the course of treatment and how such changes influence clinical outcome. Consequently, we undertook the first analysis to date of in-treatment expectancy during antidepressant treatment to identify its clinical and demographic correlates, typical trajectories, and associations with treatment outcome. Methods Data were combined from two randomized controlled trials of antidepressant medication for major depressive disorder in which baseline and in-treatment expectancy assessments were available. Machine learning methods were used to identify pre-treatment clinical and demographic predictors of expectancy. Multilevel models were implemented to test the effects of expectancy on subsequent treatment outcome, disentangling within- and between-patient effects. Results Random forest analyses demonstrated that whereas more severe depressive symptoms predicted lower pre-treatment expectancy, in-treatment expectancy was unrelated to symptom severity. At each measurement point, increased in-treatment patient expectancy significantly predicted decreased depressive symptoms at the following measurement (B = -0.45, t = -3.04, p = 0.003). The greater the gap between expected treatment outcomes and actual depressive severity, the greater the subsequent symptom reductions were (B = 0.49, t = 2.33, p = 0.02). Conclusions Greater in-treatment patient expectancy is associated with greater subsequent depressive symptom reduction. These findings suggest that clinicians may benefit from monitoring and optimizing patient expectancy during antidepressant treatment. Expectancy may represent another treatment parameter, similar to medication compliance and side effects, to be regularly monitored during antidepressant clinical management.
引用
收藏
页码:2414 / 2420
页数:7
相关论文
共 50 条
  • [31] Vortioxetine: a New Treatment for Major Depressive Disorder
    Connolly, K. Ryan
    Thase, Michael E.
    EXPERT OPINION ON PHARMACOTHERAPY, 2016, 17 (03) : 421 - 431
  • [32] Escitalopram for treatment of major depressive disorder in adults
    Llorca, PM
    Brousse, G
    Schwan, R
    ENCEPHALE-REVUE DE PSYCHIATRIE CLINIQUE BIOLOGIQUE ET THERAPEUTIQUE, 2005, 31 (04): : 490 - 501
  • [33] Updates and Trends in the Treatment of Major Depressive Disorder
    Papakostas, George I.
    Ionescu, Dawn F.
    JOURNAL OF CLINICAL PSYCHIATRY, 2014, 75 (12) : 1419 - 1421
  • [34] CURRENT DIRECTIONS IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER
    Schutter, D.
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2016, 50 : 40 - 41
  • [35] The efficacy of vortioxetine for the treatment of major depressive disorder
    Dhir, Ashish
    Sarvaiya, Jayrajsinh
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2014, 14 (12) : 1349 - 1363
  • [36] KETAMINE AS A TREATMENT FOR ADOLESCENT MAJOR DEPRESSIVE DISORDER
    Dwyer, Jennifer B.
    Bloch, Michael H.
    JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2017, 56 (10): : S176 - S176
  • [37] Consensus guidelines in the treatment of major depressive disorder
    Rush, AJ
    Crismon, ML
    Toprac, MG
    Trivedi, MH
    Rago, WV
    Shon, S
    Altshuler, KZ
    JOURNAL OF CLINICAL PSYCHIATRY, 1998, 59 : 73 - 84
  • [38] Ketamine as a Treatment for Adolescent Major Depressive Disorder
    Dwyer, Jennifer
    Sanacora, Gerard
    Bloch, Michael
    BIOLOGICAL PSYCHIATRY, 2017, 81 (10) : S405 - S405
  • [39] Escitalopram for the treatment of major depressive disorder in youth
    Ahn, Joon-Ho
    Patkar, Ashwin A.
    EXPERT OPINION ON PHARMACOTHERAPY, 2011, 12 (14) : 2235 - 2244
  • [40] Escitalopram and citalopram in the treatment of major depressive disorder
    Andersen, HF
    Lam, RW
    NORDIC JOURNAL OF PSYCHIATRY, 2005, 59 (05) : 404 - 405